stataic version 14 0 (STATA Corporation)
STATA Corporation is a verified supplier 
99
Structured Review
STATA Corporation
stataic version 14 0
Stataic Version 14 0, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 49640 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stataic+version+14/STATA+14%2E0/pm37423609-61-5-8
Average 99 stars, based on 49640 article reviews
Stataic Version 14 0, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 49640 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stataic+version+14/STATA+14%2E0/pm37423609-61-5-8
Average 99 stars, based on 49640 article reviews
stataic version 14 0 - by Bioz Stars,
2026-10
99/100 stars
Images
Related Articles
other:Article Title: Association of Ambulatory Blood Pressure Variability with Coronary Artery Calcium Article Snippet: Analyses were done using SAS 9.4 (SAS Institute Inc., Cary, NC) and figures were created using Article Title: Cognitive Behavioral Therapy for Insomnia Reduces Depression in Cancer Survivors Article Snippet: All statistical analyses were performed using Article Title: Enteric pathogen infection and consequences for child growth in young Aboriginal Australian children: a cross-sectional study Article Snippet: Data was analyzed using Article Title: Short Hypofractionated Radiotherapy in Palliation of Pediatric Malignancies: Outcomes and Toxicities Article Snippet: All statistical analyses were performed using Article Title: Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up. Article Snippet: Objectives: To examine biochemical control, survival, and late morbidity with definitive low-doserate brachytherapy (LDR-BT) for prostate cancer patients surviving ≥10 years post-treatment.. Materials and Methods: We identified 757 men with localized prostate cancer who underwent definitive LDR-BT in the period 1990-2006 and were followed for ≥10 years at our institution.. Biochemical failure-free survival (BFFS), distant metastases-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS) were selected as study endpoints. |